<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126473</url>
  </required_header>
  <id_info>
    <org_study_id>EL-004</org_study_id>
    <nct_id>NCT04126473</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele</brief_title>
  <official_title>A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eloxx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eloxx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of&#xD;
      multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X&#xD;
      allele.&#xD;
&#xD;
      Up to 16 patients will be enrolled in the trial; up 4 patients will be homozygotes to G542X,&#xD;
      and the remaining patients will be compound heterozygotes with G542X and any Class 1 or Class&#xD;
      2 mutation excluding F508del.&#xD;
&#xD;
      Each patient will receive 4 escalating doses as follows:&#xD;
&#xD;
        -  0.3 mg/kg per day SC&#xD;
&#xD;
        -  0.75 mg/kg per day SC&#xD;
&#xD;
        -  1.5 mg/kg per day SC&#xD;
&#xD;
        -  An individualized dose, as high as 3.0 mg/kg per day SC, based upon the patients&#xD;
           observed safety and tolerability, PK at previous doses and the results of laboratory&#xD;
           tests&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs associated with different dose levels of ELX-02</measure>
    <time_frame>From the time of first dosing through the follow-up visit, an average of approximately 9 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve from time zero to 24 hours (AUC0-24)</measure>
    <time_frame>Day 1 of treatment periods 1, 2, 3, and 4</time_frame>
    <description>Full PK profile 8 blood samples up to 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) on Day 1</measure>
    <time_frame>Day 1 of treatment periods 1, 2, 3, and 4</time_frame>
    <description>Full PK profile 8 blood samples over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak observed plasma concentration (Cpeak) over time</measure>
    <time_frame>Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7, and 14 of treatment period 4, sparse sampling, blood sampling at 30 min and 1 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough observed plasma concentrations (Cpredose) over time</measure>
    <time_frame>Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7 and 14 of treatment period 4, sparse blood sampling at pre-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in sweat chloride concentration</measure>
    <time_frame>From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in percent predicted forced expiratory volume (ppFEV1)</measure>
    <time_frame>From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in percent predicted forced vital capacity (ppFVC)</measure>
    <time_frame>From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in percent predicted forced expiratory flow at 25-75% (ppFEF25-75)</measure>
    <time_frame>From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>ELX-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eukaryotic ribosomal selective glycoside (ERSG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX-02</intervention_name>
    <description>ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).</description>
    <arm_group_label>ELX-02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet the following criteria to participate in this study:&#xD;
&#xD;
          1. Males and females age 18 years and above in Germany and Israel; in countries where&#xD;
             permitted, males and females age 16 years and above&#xD;
&#xD;
          2. A confirmed diagnosis of nmCF with a documented G542X mutation, homozygote, or&#xD;
             compound heterozygote with one of the specified mutations. For heterozygotes, one&#xD;
             mutation has to be G542X, and the second mutation could be and Class 1 or Class 2&#xD;
             mutation, excluding F508del. Patients with one G542X allele and a second allele that&#xD;
             is not in the above list may be potentially allowed but only after discussion on a&#xD;
             case by case basis with and written approval from the Sponsor.&#xD;
&#xD;
          3. Documented SCC ≥ 60 mEq/L&#xD;
&#xD;
          4. FEV1 ≥ 40% predicted normal for age, gender and height at Screening (Knudson Equation)&#xD;
&#xD;
          5. Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive).&#xD;
&#xD;
        Patients with any of the following characteristics/conditions will not be included in the&#xD;
        study:&#xD;
&#xD;
          1. Participation in clinical study including administration of any investigational drug&#xD;
             or device in the last 30 days or 5 half-lives (whichever is longer) prior to&#xD;
             investigational product dosing in the current study&#xD;
&#xD;
          2. History of any organ transplantation&#xD;
&#xD;
          3. Major surgery within 180 days (6 months) of Screening&#xD;
&#xD;
          4. Patients without documented prior aminoglycoside exposure who have a mitochondrial&#xD;
             mutation that has been shown to increase sensitivity to aminoglycosides&#xD;
&#xD;
          5. Known allergy to any aminoglycoside&#xD;
&#xD;
          6. Patients with any abnormality at ENT screening, that indicates the presence of a&#xD;
             vestibular toxicity associated with prior exposure to aminoglycosides.&#xD;
&#xD;
          7. Dizziness Handicap Inventory (DHI)-H score at screening &gt;16&#xD;
&#xD;
          8. Patients receiving CFTR modulators within 2 months of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eloxx Pharmaceuticals</last_name>
    <phone>1-781-577-5300</phone>
    <email>CTI@eloxxpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Whales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Hammond</last_name>
      <phone>+61 (0) 2 9515 8712</phone>
      <email>Kirsten.Hammond@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Simone Visser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Macalister</last_name>
      <phone>+61 (0)8-7074 5244</phone>
      <email>mary.mcalister@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Judith Morton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Allen-Graham</last_name>
      <phone>+61-3-90765873</phone>
      <email>J.Allen-Graham@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>John Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Essen Ruhrlandklinik</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Welsner, MD</last_name>
      <phone>0049 201 433 4501</phone>
      <email>Matthias.Welsner@rlk.uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Gina Spangel</last_name>
      <phone>0049 201 433 4893</phone>
      <email>Gina.spangel@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Welsner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Gleiber, MD</last_name>
      <phone>0049 69 6301 6336</phone>
      <email>wolfgang.gleiber@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Metskhovrishvili</last_name>
      <phone>0049 69 6301 84301</phone>
      <email>tamara.metskhovrishvili@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Gleiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Shteinberg, MD</last_name>
      <phone>+972-4-8250419</phone>
      <email>MichalSh4@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Einat Ben Shoshan</last_name>
      <phone>+972-4-8250419</phone>
      <email>EinatBe2@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Michal Shteinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malena Cohen-Cymberknoh, MD</last_name>
      <phone>+972-508-573447</phone>
      <email>malena@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Thea Pugatsch, MD</last_name>
      <phone>+972-2-5844702</phone>
      <email>Pthea@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Malena Cohen-Cymberknoh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petach Tikvah</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meir Mei-Zahav</last_name>
      <email>meir_zahav@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Zvia Dekel</last_name>
      <phone>+972-03-925-3934</phone>
      <email>Zviade@clalit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Safra Children's Hospital - Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reut Ramon</last_name>
      <phone>972-54-5200846</phone>
      <email>Reut.Ramon@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ori Efrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.eloxxpharma.com</url>
    <description>Eloxx Pharmaceuticals Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aminoglycoside</keyword>
  <keyword>Nonsense Mutation</keyword>
  <keyword>Translational read through</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

